InspireMD Makes a Significant Move with PMA Submission for CGuard™ Prime
In a promising advancement for stroke prevention technology, InspireMD, Inc. (NASDAQ: NSPR) has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) seeking approval for its cutting-edge CGuard™ Prime carotid stent system. This groundbreaking step is set to establish a new benchmark in the treatment of carotid artery disease.
The Basis of the PMA Submission
The PMA application is grounded in the successful C-GUARDIANS clinical trial, which yielded overwhelmingly positive findings. These results were first reported at the Leipzig Interventional Course (LINC) 2024. The trial involved an extensive evaluation of CGuard’s safety and efficacy in addressing carotid artery stenosis, with a particular emphasis on its effectiveness in preventing strokes. A total of 316 patients participated across 24 locations in the U.S. and Europe, marking a significant milestone in demonstrating the effectiveness of CGuard.
Noteworthy Outcomes from the C-GUARDIANS Trial
The C-GUARDIANS trial produced remarkable results, with a primary endpoint showing a major adverse event rate of just 1.95% at the one-year follow-up after the procedure. This outstanding rate makes it the lowest event rate recorded in any pivotal trial for carotid stents or embolic protection devices to date, highlighting the potential of the CGuard™ Prime to significantly enhance patient outcomes.
Insights from Leadership
Marvin Slosman, the Chief Executive Officer of InspireMD, shared his pride in reaching this milestone, stating, “The submission signifies a major advancement in our pursuit of U.S. approval for our next-generation CGuard Prime stent. We are dedicated to tackling carotid artery disease and preventing strokes, especially in light of the exceptional clinical outcomes we are achieving.” He also pointed out that the application was submitted in a modular format to facilitate a smoother review process by the FDA.
Looking Toward a U.S. Launch
As InspireMD sets its sights on the future, the company anticipates a U.S. commercial launch in the first half of 2025, pending regulatory approval. This forward-thinking schedule reflects the company's commitment to bringing advanced medical technology to market. As preparations accelerate, InspireMD is focused on developing a solid commercial and operational framework to introduce the CGuard™ Prime system successfully, ensuring it makes a substantial impact in the U.S. healthcare landscape.
About InspireMD
InspireMD is dedicated to innovation, as demonstrated by its proprietary MicroNet technology, which aims to set a new industry standard for carotid stenting. The company's overarching aim is to provide exceptional immediate results while promoting long-term, stroke-free outcomes for patients. InspireMD remains committed to protecting its intellectual property and adhering to rigorous regulatory standards, cautiously navigating the landscape for both investors and potential customers.
Investor Contact Information
If you're interested in more details, InspireMD’s investor relations team is available to assist. Craig Shore, the Chief Financial Officer, can be contacted at 888-776-6804 or by email at craigs@inspiremd.com. Additionally, Chuck Padala from LifeSci Advisors can be reached at 646-627-8390 or chuck@lifesciadvisors.com, ensuring that investor inquiries are promptly addressed.
Frequently Asked Questions
What is the objective of the PMA application submitted by InspireMD?
The PMA application seeks FDA approval for the CGuard™ Prime carotid stent system, emphasizing its role in stroke prevention.
What were the significant findings from the C-GUARDIANS clinical trial?
The trial achieved a major adverse event rate of just 1.95%, demonstrating promising safety and efficacy.
When does InspireMD expect to launch the CGuard™ Prime in the U.S.?
The company plans for a commercial launch in the U.S. during the first half of 2025, subject to regulatory approval.
What innovative technology does InspireMD employ?
InspireMD utilizes proprietary MicroNet technology to improve the safety and effectiveness of its carotid stenting products.
Who should investors contact for further information about InspireMD?
Investors can reach out to Craig Shore or Chuck Padala for any inquiries related to the company's operations and updates.
